BR112014031360A2 - derivado de metil amina cíclica heteroaromática - Google Patents
derivado de metil amina cíclica heteroaromáticaInfo
- Publication number
- BR112014031360A2 BR112014031360A2 BR112014031360A BR112014031360A BR112014031360A2 BR 112014031360 A2 BR112014031360 A2 BR 112014031360A2 BR 112014031360 A BR112014031360 A BR 112014031360A BR 112014031360 A BR112014031360 A BR 112014031360A BR 112014031360 A2 BR112014031360 A2 BR 112014031360A2
- Authority
- BR
- Brazil
- Prior art keywords
- amine derivative
- methyl amine
- cyclic methyl
- heteroaromatic cyclic
- disease
- Prior art date
Links
- -1 heteroaromatic cyclic methyl amine derivative Chemical class 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 208000035475 disorder Diseases 0.000 abstract 3
- 206010019233 Headaches Diseases 0.000 abstract 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical class NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 abstract 2
- 208000019116 sleep disease Diseases 0.000 abstract 2
- 208000020685 sleep-wake disease Diseases 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000030814 Eating disease Diseases 0.000 abstract 1
- 208000019454 Feeding and Eating disease Diseases 0.000 abstract 1
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 102000002512 Orexin Human genes 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 230000001079 digestive effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 235000014632 disordered eating Nutrition 0.000 abstract 1
- 206010013663 drug dependence Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002124 endocrine Effects 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 231100000869 headache Toxicity 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 108060005714 orexin Proteins 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Psychology (AREA)
- Addiction (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Nutrition Science (AREA)
- Endocrinology (AREA)
- Anesthesiology (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
resumo derivado de metil amina cíclica heteroaromática um derivado de metil amina cíclica heteroaromática representado pela fórmula (ia) ou um sal farmaceuticamente deste é útil para o tratamento ou profilaxia de doenças tais como distúrbio do sono, depressão, distúrbio de ansiedade, distúrbio do pânico, esquizofrenia, dependência medicamentosa, doença de alzheimer, doença de parkinson, doença de huntington, distúrbio alimentar, cefalalgia, hemicrania, dor, doenças digestivas, epilepsia, inflamação, doenças imuno-relacionadas, doenças endócrino-relacionadas e hipertensão, com base em uma atividade antagonista do receptor de orexina (ox).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012-135277 | 2012-06-15 | ||
| JP2012135277 | 2012-06-15 | ||
| PCT/JP2013/066322 WO2013187467A1 (ja) | 2012-06-15 | 2013-06-13 | ヘテロ芳香環メチル環状アミン誘導体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112014031360A2 true BR112014031360A2 (pt) | 2017-06-27 |
| BR112014031360B1 BR112014031360B1 (pt) | 2022-04-12 |
Family
ID=49758285
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112014031360-1A BR112014031360B1 (pt) | 2012-06-15 | 2013-06-13 | Composto, composição farmacêutica e medicamento terapêutico ou preventivo |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US9266870B2 (pt) |
| EP (1) | EP2862860B1 (pt) |
| JP (1) | JP5896319B2 (pt) |
| KR (1) | KR102098977B1 (pt) |
| CN (1) | CN104350053B (pt) |
| AU (1) | AU2013275210B2 (pt) |
| BR (1) | BR112014031360B1 (pt) |
| CA (1) | CA2876253C (pt) |
| CY (1) | CY1118848T1 (pt) |
| DK (1) | DK2862860T3 (pt) |
| ES (1) | ES2613663T3 (pt) |
| HK (1) | HK1202540A1 (pt) |
| HR (1) | HRP20161797T1 (pt) |
| HU (1) | HUE031538T2 (pt) |
| IL (1) | IL236140A (pt) |
| IN (1) | IN2014DN10490A (pt) |
| LT (1) | LT2862860T (pt) |
| ME (1) | ME02606B (pt) |
| MX (1) | MX355660B (pt) |
| MY (1) | MY171464A (pt) |
| NZ (1) | NZ702647A (pt) |
| PH (1) | PH12014502750B1 (pt) |
| PL (1) | PL2862860T3 (pt) |
| PT (1) | PT2862860T (pt) |
| RS (1) | RS55675B1 (pt) |
| RU (1) | RU2639869C2 (pt) |
| SG (1) | SG11201408327XA (pt) |
| SI (1) | SI2862860T1 (pt) |
| TW (1) | TWI583683B (pt) |
| WO (1) | WO2013187467A1 (pt) |
| ZA (1) | ZA201409168B (pt) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2012004753A (es) | 2009-10-23 | 2012-09-07 | Janssen Pharmaceutica Nv | Octahidropirrolo[3,4-c]pirrolos disustituidos como moduladores del receptor de orexina. |
| JP2017024990A (ja) * | 2013-12-13 | 2017-02-02 | 大正製薬株式会社 | オキサゾリジン及びオキサジナン誘導体 |
| CN105814042B (zh) * | 2013-12-13 | 2018-09-28 | 大正制药株式会社 | 噁嗪烷化合物的晶形及其制造方法 |
| CN104370755B (zh) * | 2014-08-18 | 2017-04-12 | 江西隆莱生物制药有限公司 | 一种光学活性的3‑氨基丁醇和3‑氨基丁酸的制备方法 |
| JP2018188364A (ja) * | 2015-10-02 | 2018-11-29 | 大正製薬株式会社 | 複素芳香環誘導体 |
| HUE058759T2 (hu) | 2016-03-10 | 2022-09-28 | Janssen Pharmaceutica Nv | Módszerek depresszió kezelésére orexin-2 receptor antagonisták alkalmazásával |
| CN108129426B (zh) * | 2016-12-01 | 2021-06-29 | 中国科学院大连化学物理研究所 | 一种2,5-二氰基呋喃催化加氢合成2,5-二甲胺基呋喃的方法 |
| JOP20190156B1 (ar) * | 2016-12-23 | 2023-09-17 | Bayer Pharma AG | أميدات عطرية لحمض الكربوكسيليك بصفتها مضادات لمستقبلة البراديكينين b1 |
| WO2019013244A1 (ja) | 2017-07-13 | 2019-01-17 | 大正製薬株式会社 | （２ｓ）－２－［（１ｈ－ピラゾール－１－イル）メチル］－１，３－オキサジナン誘導体の製造方法 |
| CN110967321A (zh) * | 2018-09-29 | 2020-04-07 | 泰州医药城国科化物生物医药科技有限公司 | 一种用于均一体系细胞荧光检测钙流方法 |
| CA3184307A1 (en) | 2020-05-22 | 2021-11-25 | Neuway Pharma Gmbh | Vlp for the treatment of leukodystrophies |
| CN113336655A (zh) * | 2020-12-30 | 2021-09-03 | 江西迪赛诺制药有限公司 | 一种(r)-3-氨基丁醇的制备方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0115862D0 (en) | 2001-06-28 | 2001-08-22 | Smithkline Beecham Plc | Compounds |
| US7169744B2 (en) * | 2002-06-06 | 2007-01-30 | Procter & Gamble Company | Organic catalyst with enhanced solubility |
| WO2008062878A1 (fr) * | 2006-11-22 | 2008-05-29 | Nihon Nohyaku Co., Ltd. | Nouveau dérivé de pyrazole, agent de lutte contre des organismes nuisibles et utilisation de l'agent de lutte contre des organismes nuisibles |
| AU2008223546A1 (en) | 2007-03-02 | 2008-09-12 | Merck Sharp & Dohme Corp. | Bipyridine carboxamide orexin receptor antagonists |
| UA99620C2 (en) * | 2007-05-23 | 2012-09-10 | Мерк Шарп Энд Доме Корп. | Pyridyl piperidine orexin receptor antagonists |
| WO2009020642A1 (en) * | 2007-08-09 | 2009-02-12 | Merck & Co., Inc. | Pyridine carboxamide orexin receptor antagonists |
| WO2010038200A1 (en) * | 2008-10-01 | 2010-04-08 | Actelion Pharmaceuticals Ltd | Oxazolidine compounds as orexin receptor antagonists |
| KR20110071004A (ko) | 2008-10-14 | 2011-06-27 | 액테리온 파마슈티칼 리미티드 | 페네틸아미드 유도체 및 이의 헤테로시클릭 유사체 |
| CA2739917A1 (en) | 2008-10-21 | 2010-04-29 | Merck Sharp & Dohme Corp. | 2,5-disubstituted morpholine orexin receptor antagonists |
| US8399494B2 (en) | 2008-10-30 | 2013-03-19 | Merck Sharp & Dohme Corp. | 2,5-disubstituted phenyl carboxamide orexin receptor antagonists |
| JP5635991B2 (ja) * | 2008-10-30 | 2014-12-03 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | イソニコチンアミドオレキシン受容体アンタゴニスト |
| KR20140000703A (ko) | 2010-12-17 | 2014-01-03 | 다이쇼 세이야꾸 가부시끼가이샤 | 피라졸 유도체 |
| WO2012153729A1 (ja) | 2011-05-10 | 2012-11-15 | 大正製薬株式会社 | ヘテロ芳香環誘導体 |
-
2013
- 2013-06-13 PL PL13804876T patent/PL2862860T3/pl unknown
- 2013-06-13 MX MX2014015077A patent/MX355660B/es active IP Right Grant
- 2013-06-13 SI SI201330457A patent/SI2862860T1/sl unknown
- 2013-06-13 BR BR112014031360-1A patent/BR112014031360B1/pt active IP Right Grant
- 2013-06-13 NZ NZ702647A patent/NZ702647A/en unknown
- 2013-06-13 ES ES13804876.4T patent/ES2613663T3/es active Active
- 2013-06-13 CN CN201380031372.4A patent/CN104350053B/zh active Active
- 2013-06-13 LT LTEP13804876.4T patent/LT2862860T/lt unknown
- 2013-06-13 RS RS20170123A patent/RS55675B1/sr unknown
- 2013-06-13 AU AU2013275210A patent/AU2013275210B2/en active Active
- 2013-06-13 EP EP13804876.4A patent/EP2862860B1/en active Active
- 2013-06-13 HU HUE13804876A patent/HUE031538T2/en unknown
- 2013-06-13 CA CA2876253A patent/CA2876253C/en active Active
- 2013-06-13 KR KR1020147035124A patent/KR102098977B1/ko active IP Right Grant
- 2013-06-13 DK DK13804876.4T patent/DK2862860T3/en active
- 2013-06-13 IN IN10490DEN2014 patent/IN2014DN10490A/en unknown
- 2013-06-13 PT PT138048764T patent/PT2862860T/pt unknown
- 2013-06-13 US US14/407,353 patent/US9266870B2/en active Active
- 2013-06-13 WO PCT/JP2013/066322 patent/WO2013187467A1/ja active Application Filing
- 2013-06-13 MY MYPI2014703693A patent/MY171464A/en unknown
- 2013-06-13 ME MEP-2017-34A patent/ME02606B/me unknown
- 2013-06-13 RU RU2015101102A patent/RU2639869C2/ru active
- 2013-06-13 JP JP2014521401A patent/JP5896319B2/ja active Active
- 2013-06-13 SG SG11201408327XA patent/SG11201408327XA/en unknown
- 2013-06-14 TW TW102121127A patent/TWI583683B/zh active
-
2014
- 2014-12-08 IL IL236140A patent/IL236140A/en active IP Right Grant
- 2014-12-09 PH PH12014502750A patent/PH12014502750B1/en unknown
- 2014-12-12 ZA ZA2014/09168A patent/ZA201409168B/en unknown
-
2015
- 2015-03-26 HK HK15103061.1A patent/HK1202540A1/xx unknown
-
2016
- 2016-12-27 HR HRP20161797TT patent/HRP20161797T1/hr unknown
-
2017
- 2017-03-08 CY CY20171100300T patent/CY1118848T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112014031360A2 (pt) | derivado de metil amina cíclica heteroaromática | |
| BR112014031109A2 (pt) | derivado de anel heteroaromático de alquila de cadeia ramificada | |
| BR112016024472A2 (pt) | composto, medicamento, métodos para modulação alostérica positiva e para profilaxia ou tratamento de doenças, e, uso de um composto | |
| MX349754B (es) | Metodo para la administracion de 4-((1r,3s)-6-cloro-3-fenil-indan- 1-il)-1,2,2-trimetil-piperazina y de sus sales en el tratamiento de esquinozofrenia. | |
| MA32898B1 (fr) | Modulateurs allosteriques positifs du recepteur m1 d'arylmethylbenzoquinazolinone | |
| MX2017006483A (es) | Compuestos aminopirazina con propiedades antagonistas a2a. | |
| BR112013002250A2 (pt) | composto, medicamento, método para a profilaxia ou tratamento de depressão, esquisofrenia, mal de alzheimer ou distúrbio de hiperatividade e déficit de atenção, e, uso de um composto. | |
| UY33863A (es) | Metodos y medicamentos para el tratamiento de la enfermedad de alzheimer | |
| MX2010002899A (es) | Derivados de azaciclilisoquinolinona e isoindolinona como antagonistas de la histamina-3. | |
| EA201171172A1 (ru) | Применение в терапии производных хиназолиндиона | |
| NZ605431A (en) | D2 antagonists, methods of synthesis and methods of use | |
| UA109260C2 (uk) | Хромонові похідні, спосіб їх одержання та їх терапевтичні застосування | |
| BR112012004851B8 (pt) | uso de um derivado de tiazol | |
| PH12014501195A1 (en) | Novel 2h-indazoles as ep2, receptor antagonists | |
| MX2015013328A (es) | Uso de antagonistas del receptor de ep4 en el tratamiento de enfermedad de cartilago. | |
| UA117154C2 (uk) | Антагоністи s1p3 | |
| JO3128B1 (ar) | بيبرازينو-3-فينيل-اندانيس معالج بالديتوريوم لمعالجة انفصام الشخصية- 1 | |
| MX2013002956A (es) | Arilsulfonamidas para el tratamiento de enfermedades del sistema nervioso central. | |
| BR112014006675A2 (pt) | derivados de metanossulfonamida substituídos como ligantes de receptor vaniloide | |
| BR112014011262A2 (pt) | carboxamida com base em pirazolila substituída e derivados de ureia que portam uma porção de fenila substituída com um grupo contendo o como ligantes de receptor vaniloide | |
| BR112017014179A2 (pt) | métodos de produção de um composto e de um cristal, e, cristal de um composto. | |
| BR112014010957A2 (pt) | derivados de ureia e carboxamida com base em pirazolila substituída transportando uma porção de fenila substituída por um grupo contendo n como ligantes de receptor de vaniloide | |
| TH152864A (th) | อนุพันธ์เฮเทอโรอะโรมาติกเมทธิลไซคลิคเอมีน | |
| BR112017023894A2 (pt) | derivados de etinila | |
| TH154855A (th) | อนุพันธ์วงแอลคิลเฮเทอโรแอโรแมทิคชนิดโซ่กิ่ง |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/06/2013, OBSERVADAS AS CONDICOES LEGAIS. |